SEP 01, 2020 3:18 PM PDT

First Novel Compounds to Inhibit Cancer-Linked Enzymes

WRITTEN BY: Nouran Amin

Researchers from the University of Michigan Rogel Cancer Center have worked on creating a therapeutic-based compound that can block the activity of cancer-linked enzymes. The particular family of enzymes examined in the study is known as the nuclear receptor-binding SET domain (NSD). The enzymes are part of a family of histone methyltransferases that have long been studied as an attractive drug target. However, the efforts to attack the activity of these enzymes have been challenging because of the shape of the binding sites where drug-like molecules are supposed to attach.

Learn more about enzymatic activity in cancer:

To develop the first-in-class inhibitors, Tomasz Cierpicki, Ph.D., and Jolanta Grembecka, used multiple approaches including X-ray crystallography and nuclear magnetic resonance. The work has led to the inhibition of a key protein known as NSD1. Specifically, they developed a compound known as ‘BT5’ and was shown promise in leukemic cells.

Findings were published in Nature Chemical Biology.

"Our study, which was years in the making, demonstrates that targeting this key enzyme with small-molecule inhibitors is a feasible approach," says Cierpicki, an associate professor of biophysics and pathology at U-M. "These findings will facilitate the development of the next generation of potent and selective inhibitors of these enzymes, which are overexpressed, mutated or undergo translocations in several types of cancer."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 16, 2020
Drug Discovery & Development
Could Cat Drugs Treat COVID-19 in Humans?
AUG 16, 2020
Could Cat Drugs Treat COVID-19 in Humans?
While COVID-19 may not affect cats much, felines are known to contract another kind of coronavirus that can sometimes be ...
AUG 24, 2020
Neuroscience
Researchers Crowdfund $30 Million for Psychedelic Therapy for PTSD
AUG 24, 2020
Researchers Crowdfund $30 Million for Psychedelic Therapy for PTSD
In a historic feat, the Multidisciplinary Association for Psychedelic Studies (MAPS) has raised $30 million to complete ...
AUG 25, 2020
Drug Discovery & Development
Drug Combination Reduces Cardiovascular Complications
AUG 25, 2020
Drug Combination Reduces Cardiovascular Complications
According to a new study, combining the drugs hydroxychloroquine (HCQ) and azithromycin (AZM) was shown to reduce cardio ...
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
SEP 10, 2020
Drug Discovery & Development
Improving Chemotherapeutic Delivery
SEP 10, 2020
Improving Chemotherapeutic Delivery
One particular form of stubborn cancer, known as hepatocellular carcinoma, has been challenging to treat and as a result ...
SEP 22, 2020
Drug Discovery & Development
New Treatment for Mouth-Hand-Foot Disease
SEP 22, 2020
New Treatment for Mouth-Hand-Foot Disease
A study appearing next week in the journal Nature Communications offers some good news in the search for antiviral drugs ...
Loading Comments...